Interest of Metabolomic and Immune Profiling in the Development of Pancreatic Fistulas After Duodenopancreatectomy

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Pancreatoduodenectomy is the standard surgical operation for benign or malign pancreatic lesions. Pancreatic Fistula (PF) or Postpancreatectomy Acute Pancreatitis (PPAP) are the major complications associated with that type of surgery. We need to develop preventive measures for these complications, which requires a better understanding of their physiopathology. The aim of this prospective monocentric and observational study is to identify predictive biomarkers and/or risk factors for PF or PPAP using metabolomics. The Profiling of circulating metabolites is indeed an original and promising approach for this purpose. We will also investigate the patient's immune status and its association with the occurrence of post-surgical complications. Participants will be adult patients scheduled to undergo elective pancreaticoduodenectomy. Surgery and patient's management will be as usual. During surgery, a fragment (0.1-0.2 g) of non-tumoral pancreatic tissue will be removed and frozen at -80°C for metabolomic analysis. For immunological assessment, 4 blood samples will be collected (before surgery and then 7 days, 1 and 3 months after, blood sampling).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• patients scheduled to undergo elective pancreaticoduodenectomy

• Non-opposition of the subject to participate in the study.

• Affiliated to the French social security system (CMU included).

Locations
Other Locations
France
University Hospital of Besançon
RECRUITING
Besançon
Contact Information
Primary
Alexandre DOUSSOT, MD, PhD
adoussot@chu-besancon.fr
+33381668343
Backup
astrid POZET
apozet@chu-besancon.fr
+33381218988
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2026-05-30
Participants
Target number of participants: 80
Sponsors
Leads: Centre Hospitalier Universitaire de Besancon

This content was sourced from clinicaltrials.gov